FMP

FMP

Enter

RLMD - Relmada Therapeutics...

Terminal Value of Relmada Therapeutics, Inc.(RLMD), Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various pr

photo-url-https://financialmodelingprep.com/image-stock/RLMD.png

Relmada Therapeutics, Inc.

RLMD

NASDAQ

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

3 USD

-0.03 (-1%)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep